HITK should focus selling Zolpimist on CNS and Women health arenas. They should build sell force team for Zolpimist. Zolpimist is an excellent product for 3 billion market. This is a brand product and not generic. Gp market is very hard to penetrate. Focus focus focus.
Just read about menopause women difficulty sleeping.
The people on ECR have no experience with brand product as to replace by professional people or find co fo Orion tp the product.
Non of HITK's products unque therefore their product life value is limited. Zolpimist is unique for huge market.
Giving the product to ECR with limited financing was a big mistake.
HITK could do much better work. Spending $15 million every year for the next three years could bring $50 -$100 million in revenues.
The money should spend wisely for menpower and promotion. This is the basic material in marketing….